BidaskClub upgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a buy rating in a report published on Saturday, BidAskClub reports.

Other research analysts have also recently issued reports about the company. Wedbush upgraded Five Prime Therapeutics from a neutral rating to an outperform rating and upped their price target for the stock from $5.00 to $9.00 in a research note on Monday, June 22nd. Zacks Investment Research cut Five Prime Therapeutics from a buy rating to a hold rating in a research note on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. cut Five Prime Therapeutics from a neutral rating to an underweight rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $7.00.

NASDAQ:FPRX opened at $6.70 on Friday. The company has a quick ratio of 7.82, a current ratio of 7.82 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average is $5.01 and its two-hundred day moving average is $4.19. Five Prime Therapeutics has a 52 week low of $1.75 and a 52 week high of $7.25. The stock has a market capitalization of $249.85 million, a price-to-earnings ratio of -1.93 and a beta of 2.95.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.10. Five Prime Therapeutics had a negative return on equity of 72.79% and a negative net margin of 679.63%. The company had revenue of $8.41 million for the quarter, compared to analysts’ expectations of $6.60 million. On average, sell-side analysts expect that Five Prime Therapeutics will post -2.44 EPS for the current fiscal year.

In related news, major shareholder Bvf Partners L. P/Il acquired 293,587 shares of Five Prime Therapeutics stock in a transaction dated Thursday, May 14th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $1,203,706.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC increased its holdings in Five Prime Therapeutics by 21.6% in the first quarter. Squarepoint Ops LLC now owns 28,576 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 5,076 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Five Prime Therapeutics by 16.4% in the first quarter. Wells Fargo & Company MN now owns 33,257 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 4,685 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Five Prime Therapeutics in the fourth quarter valued at $94,000. Cubist Systematic Strategies LLC increased its holdings in Five Prime Therapeutics by 106.4% in the fourth quarter. Cubist Systematic Strategies LLC now owns 22,818 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 11,764 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC grew its holdings in shares of Five Prime Therapeutics by 66.7% during the first quarter. Franklin Street Advisors Inc. NC now owns 50,000 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 20,000 shares during the last quarter. 68.02% of the stock is currently owned by hedge funds and other institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Further Reading: How can investors invest in the S&P/TSX Index?

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.